7535-59-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-Benzyl-5-carboxy-2-pyrrolidinone is used as a key intermediate in the synthesis of various pharmaceuticals for the treatment of cancer and neurological disorders. Its ability to inhibit specific enzymes and receptors makes it a promising candidate for drug development.
Used in Organic Chemistry:
(S)-1-Benzyl-5-carboxy-2-pyrrolidinone serves as a building block in organic chemistry, contributing to the synthesis of complex organic molecules and compounds.
Used as a Chiral Auxiliary:
In asymmetric synthesis, (S)-1-Benzyl-5-carboxy-2-pyrrolidinone is used as a chiral auxiliary to induce enantioselectivity, enabling the production of specific enantiomers with desired biological activities.
Used as a Ligand in Metal-Catalyzed Reactions:
(S)-1-Benzyl-5-carboxy-2-pyrrolidinone also functions as a ligand in metal-catalyzed reactions, facilitating the formation of desired products with improved efficiency and selectivity.

Upstream product

• 77539-18-5 (S)-(+)-2-benzylamino glutaric acid 
• 103301-78-6 methyl (2S)-1-benzyl-5-pyrrolidone-2-carboxylate 
• 90741-27-8 (S)-tert-butyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 
• 100-44-7 benzyl chloride 
• 98-79-3 L-Pyroglutamic acid 
• 35418-16-7 L-t-butyl pyroglutamate 
• 100-39-0 benzyl bromide 
• 56-86-0 L-glutamic acid 
• 100-52-7 benzaldehyde 
• 4931-66-2 methyl (S)-pyroglutamate 
• 137641-62-4 (S)-(+)-1-(benzyl)-5-oxopyrrolidine-2-carboxylic acid ethyl ester 

Downstream Products

• 103301-78-6 methyl (2S)-1-benzyl-5-pyrrolidone-2-carboxylate 
• 272784-43-7 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-(4-nitro-phenyl)-propionic acid methyl ester 
• 378238-39-2 9-(N-benzyl-(S)-pyroglutamyl)-β-carboline 
• 412352-94-4 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-(4-trifluoromethanesulfonyloxy-phenyl)-propionic acid methyl ester 
• 412353-17-4 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-propionic acid methyl ester 
• 459454-27-4 methyl 3-benzyloxycarbonyl-1-[(1-benzyl-5-oxopyrrolidine-2(S)-carbonyloxy)acetyl]-2-oxoimidazolidine-4(S)-carboxylate 

Relevant academic research and scientific papers

Substituted 5-oxo-pyrrolidine derivative, and preparation method and applications thereof

The invention belongs to the technical field of medicine, relates to a substituted 5-oxo-pyrrolidine derivative disclosed in generation formula I, and a preparation method and applications thereof, and more specifically relates to applications of the substituted 5-oxo-pyrrolidine derivative in preparation of anti-cerebral ischemia medicines as a nerve protective agent, and a pharmaceutical composition taking the substituted 5-oxo-pyrrolidine derivative and a pharmaceutically acceptable salt of the substituted 5-oxo-pyrrolidine derivative as active components. The pharmaceutical composition contains the substituted 5-oxo-pyrrolidine derivative and a pharmaceutical excipient and/or a diluent of the substituted 5-oxo-pyrrolidine derivative. In the general formula I, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Y, and n are defined in the patent specification and patent claims.

A the non-peptide class perishes weakly inhibiting protein antagonists and its synthetic method and application (by machine translation)

This invention discloses a kind of the non-peptide class perishes weakly inhibiting protein antagonist and method for preparing the same and application, which aims to provide a better anticancer effect with the non-peptide class perishes weakly inhibitin

An efficient and straight forward strategy for the synthesis of enantiomerically pure (S)-1-benzyl-5-(alkyl/aryl amino) methyl-pyrrolidin-2-ones

A simple, efficient and straightforward strategy for the synthesis of enantiomerically pure (S)-5-((alkyl/aryl amino) methyl)-pyrrolidin-2-ones from N-benzyl-5(S)-pyroglutaminol through Mitsunobu reaction has been described. These pyrrolidin-2-ones have great potential to act as asymmetric precursors for the synthesis of bioactive compounds/ natural products requiring suitably substituted aminomethyl group at C-5 of native pyrrolidin-2-ones.

3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS

The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation

A series of chiral lactam carboxamides of aminomethylpiperidine were synthesized and investigated for the collagen induced in vitro anti-platelet efficacy and collagen plus epinephrine induced in vivo pulmonary thromboembolism. The compound 31a (30 μM/kg) displayed a remarkable antithrombotic efficacy (60% protection) which was sustained for more than 24 h and points to its excellent bioavailability. The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro. Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation. The pharmacokinetic study of 31a indicated very faster absorption, prolonged and constant systemic exposure and thereby exhibiting better therapeutic response.

An efficient and straight forward synthesis of (5S)-1-benzyl-5-(1H- imidazol-1-ylmethyl)-2-pyrrolidinone (MM1): A novel antihypertensive agent

(5S)-1-benzyl-5-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone and its closely related analog was synthesized from (S)-pyroglutaminol and imidazole or substituted imidazole using Mitsunobu reaction as the key step. Springer Science+Business Media, LLC 2010.

Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X7 receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X7 antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies.

Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflamma

Di-μ-hydroxy-bis(N,N,N′,N′-tetramethylenediamine)-copper(II) chloride [Cu(OH)·TMEDA]2Cl2: An efficient, practical catalyst for benzylation and allylation of amides

An efficient protocol for the benzylation or allylation of amides using the corresponding benzyl or allyl chlorides as electrophiles under basic conditions with commercially available 5 mol % of [Cu(OH)TMEDA]2Cl2 as catalyst was developed. Under these conditions, unprotected amino acids were benzylated without any racemization.

Dimethylaluminum methyltellurate, a new reagent for the cleavage of hindered methyl esters under exceptionally mild conditions by a novel mechanism

An efficient and effective new reagent (Me2AlTeMe)2 has been developed for the conversion of methyl esters to the corresponding carboxylic acids in toluene solution at 23°C.